Skip to main content
. 2021 Sep 16;11:742666. doi: 10.3389/fonc.2021.742666

Figure 2.

Figure 2

Evolution of the lesions. (A) Basal evaluation; (B) 2 weeks after the first ECT; (C) 2 months after the first ECT and 1 month after 1 cycle of anti-PD1; (D) 3 months after the first ECT and 1 month after 2 cycles of anti-PD1; (E) 1 week after the second ECT; (F) 2 months after second ECT and completion of 5 cycles of anti-PD1; (G) 3 months after second ECT and anti-PD1 temporary suspension for toxicity; (H) 17 months after the second ECT and after 15 cycles of anti-PD1.